Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Tax Provisions (2022 - 2025)

Oramed Pharmaceuticals' Tax Provisions history spans 3 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Tax Provisions changed N/A year-over-year to $8.5 million; the TTM value through Dec 2025 reached $20.1 million, changed N/A, while the annual FY2025 figure was $11.3 million, 255.26% up from the prior year.
  • Tax Provisions reached $8.5 million in Q4 2025 per ORMP's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $11.1 million in Q3 2025 to a low of -$126000.0 in Q2 2025.
  • Average Tax Provisions over 3 years is $3.3 million, with a median of $1.1 million recorded in 2024.
  • The largest YoY upside for Tax Provisions was 876.35% in 2025 against a maximum downside of 107.71% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $100000.0 in 2022, then surged by 1033.0% to $1.1 million in 2024, then soared by 653.84% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Tax Provisions are $8.5 million (Q4 2025), $11.1 million (Q3 2025), and -$126000.0 (Q2 2025).